Zodasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins across all dose levels at Week 24 Data presented at European Atherosclerosis Society 92nd Congress and
- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol
- Data presented at European Atherosclerosis Society 92nd Congress.